KalVista Pharmaceuticals (KALV) Tuesday has completed enrollment for the KONFIDENT-KID clinical trial, evaluating sebetralstat, an investigational oral plasma kallikrein inhibitor, in pediatric patients aged 2-11 with hereditary angioedema - HAE.
The trial, initially planned for 24 participants, expanded to approximately 36 due to strong interest, spanning seven countries across North America, Europe, and Asia.
The study will assess safety, pharmacokinetics, and efficacy over a year, using a proprietary pediatric oral disintegrating tablet - ODT formulation. If approved, sebetralstat would become the first oral on-demand therapy for this age group and only the second FDA-approved treatment of its kind. Initial results are expected later this year, with a supplemental new drug application - sNDA filing anticipated by mid-2026.
Tuesday, KALV closed at $12.50, rising 2.04%, and is currently trading after hours at $12.55, up 0.40%, on the Nasdaq Global Market.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.